Nevisense Boosts Clinician Confidence in Early Melanoma Diagnosis

Nevisense increased clinician's sensitivity for melanoma and dysplastic nevi from 70 percent to 84 percent. 

Nevisense provides valuable diagnostic guidance for clinicans when evaluating atypical pigmented skin lesions, according to a new study.

The Nevisense method uses small electrical impulses to detect cellular irregularities beneath the skin’s surface.

In the pilot study, mean confidence for clinicians in correctly identifying the disease diagnosis significantly increased when Nevisense was added to the evaluation of clinical and dermoscopic images of skin lesions suspicious for melanoma. Specifically, Nevisense increased clinician's sensitivity for melanoma and dysplastic nevi from 70 percent to 84 percent. 

"While the performance of Nevisense as a diagnostic aid in the management of atypical pigmented skin lesions suspicious for melanoma has been previously demonstrated, its impact on clinician confidence in their biopsy decisions has not been described,” says study author David Polsky, MD, PhD, the Alfred W. Kopf, MD Professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, NYU Langone Health in New Yorl City, in a news release. “Adding Nevisense to these evaluations also significantly increased diagnostic accuracy and biopsy sensitivity for melanoma." 

"This study further validates Nevisense as a valuable tool for the early detection of melanoma. The article presents additional evidence that Nevisense can help clinicians of all experience levels improve their ability to accurately identify lesions that require treatment and to be more confident in their clinical management decisions", adds Simon Grant, CEO of SciBase, the developer of Nevisense.

 The study appears in SKIN - The Journal of Cutaneous Medicine's website.